Agenus is a startup based in the United States, most recent round Series-c-plus, 1 tracked investor.
Based in the United States, Agenus is a startup founded in 1994. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Agenus develops cancer immunotherapies, including a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies that target the immune system for cancer therapy. The company has collaborations on checkpoint modulators with partners such as Merck and Incyte and is publicly listed on NASDAQ.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.